|PCI Biotech: First quarter 2017 report and presentation|
|By: Nasdaq / GlobenewsWire - 16 May 2017||Back to overview list
Oslo, 16 May 2017 - Please find enclosed the financial report and presentation for first quarter 2017.
CEO, Per Walday, comments:
The near-term focus for the company is to get regulatory clarity on the requirements for a marketing authorisation for fimaporfin in bile duct cancer, initiate the Phase I extension and to complete the clinical translation of the promising preclinical results with fimaVacc".
A presentation in English will be held today, Tuesday 16 May 2017, at Oslo Cancer Cluster Innovation Park.
Time: Tuesday May 16 2017, 09.00am -10.00am CEST (local time).
The presentation can be followed as a live audiocast from Hegnar TV ( http://webtv.hegnar.no/presentation.php?webcastId=52726738 ), and it will be possible to post questions through the webcast console.
About PCI Biotech
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead
programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products.
applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies.
utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCI Biotech Holding via GlobeNewswire
Copyright 2017 Nasdaq / GlobenewsWire
|Back to overview list|